To confirm MC1R expression in the melanoma cell line B16/F1 and to assess the affinity of DOTA-NAPamide towards the receptor, competitive radioligand binding and saturation binding assays using 125I-labeled NDP-MSH were performed (Fig 1A). Here, MC1R is linked to melanoma.